Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 1
2010 2
2011 1
2012 3
2013 2
2014 1
2016 2
2017 5
2018 1
2019 2
2020 3
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Desmoid Tumors: A Comprehensive Review.
Bektas M, Bell T, Khan S, Tumminello B, Fernandez MM, Heyes C, Oton AB. Bektas M, et al. Among authors: oton ab. Adv Ther. 2023 Sep;40(9):3697-3722. doi: 10.1007/s12325-023-02592-0. Epub 2023 Jul 12. Adv Ther. 2023. PMID: 37436594 Free PMC article. Review.
Disease and economic burden of surgery in desmoid tumors: a review.
Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Fernandez MM, et al. Among authors: oton ab. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(6):607-618. doi: 10.1080/14737167.2023.2203915. Epub 2023 Apr 26. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 37099290 Review.
Debunking Myths While Understanding Limitations.
Hess LM, Winfree KB, Muehlenbein CE, Zhu YE, Oton AB, Princic N, Aggarwal H. Hess LM, et al. Among authors: oton ab. Am J Public Health. 2020 May;110(5):e2. doi: 10.2105/AJPH.2020.305603. Am J Public Health. 2020. PMID: 32267743 Free PMC article. No abstract available.
MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N, Oton AB, Hirsch FR, Bunn P. Peled N, et al. Among authors: oton ab. Immunotherapy. 2009 Jan;1(1):19-25. doi: 10.2217/1750743X.1.1.19. Immunotherapy. 2009. PMID: 20635969 Review.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Garon EB, Scagliotti GV, Gautschi O, Reck M, Thomas M, Iglesias Docampo L, Kalofonos H, Kim JH, Gans S, Brustugun OT, Orlov SV, Cuyun Carter G, Zimmermann AH, Oton AB, Alexandris E, Lee P, Wolff K, Stefaniak VJ, Socinski MA, Pérol M. Garon EB, et al. Among authors: oton ab. ESMO Open. 2020 Jan;5(1):e000567. doi: 10.1136/esmoopen-2019-000567. ESMO Open. 2020. PMID: 31958290 Free PMC article. Clinical Trial.
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. Weickhardt A, et al. Among authors: oton a. J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11. J Thorac Oncol. 2012. PMID: 22237261 Free PMC article. Clinical Trial.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
29 results